We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Clorox Company (CLX - Free Report) looks good on the back of its long-term initiatives, solid fourth-quarter fiscal 2017 results, strong brand portfolio and a disciplined capital strategy.
Let’s find out more about the stock, which also boasts a long-term earnings growth rate of 6.6%.
2020 Strategy
Clorox remains keen on the smooth execution of its 2020 Strategy, which is aimed at boosting growth for the improvement of categories and overall market share. In fact, the whole strategy is aimed at achieving certain long-term aspirations, including growing net sales by 3−5%, improvement of EBIT margin by 25−50 basis points, and generating free cash flow of 10−12% of sales, all on a yearly basis.
We note that the company is well on track with its 2020 Strategy, which is meant to be achieved through key accelerators like investment in brands; development of eCommerce; technological advancements; enhancement of growth culture and focus on the 3Ds – desire, decision and delight.
Sturdy Q4 Results & Favorable Outlook
Clorox posted solid fourth-quarter fiscal 2017 results, wherein both the top and bottom lines grew year over year and topped estimates. Notably, earnings marked the third straight quarter of a beat, while sales reverted to its positive surprise track after a miss in the last quarter.
While the bottom line gained from strong sales and cost-savings, the top line was fueled by higher volumes, better International pricing and benefits from RenewLife (acquired in May 2016). Further, sales grew year over year in each segment in the quarter. The company’s fiscal 2017 performance also remained robust with solid top- and bottom-line growth year over year. (Read More: Clorox Q4 Earnings & Sales Beat the Zacks Consensus)
Further, management is encouraged by its International operations, and expects pricing and cost savings to continue driving results. It expects fiscal 2018 to represent another year of strong earnings and sales growth. For fiscal 2018, Clorox expects sales to grow in a range of 2–4%, and earnings from continuing operations to rise 3–7% year over year.
Other Strengths
We believe Clorox's diversified brand portfolio places the company well above its peers to generate above-average industry growth and sustain itself in the currently challenging environment.
In fact, its focus on boosting sales through brands is well-evident from its constant innovations and marketing strategies to drive top-line growth. Alongside, it maintains a disciplined capital allocation strategy, making investments to develop its business while using the excess cash to lower debts and enhance shareholder returns.
Concerns/Weakness
However, the stock is not devoid of concerns/headwinds, which might dampen its performance in the near term. Clorox’s significant international presence exposes it to major foreign currency risks (especially in Argentina), which have hurt results for a while in the past. Also, currency headwinds are expected to have one point adverse impact on sales growth in fiscal 2018.
Additionally, Clorox faces intense competition from other well-established players in the consumer products industry, such as Church & Dwight Co., Inc. (CHD - Free Report) , Colgate-Palmolive Company (CL - Free Report) and The Procter & Gamble Company (PG - Free Report) on the basis of pricing, promotional activities and new product introductions.
Bottom Line
While these headwinds, along with a retail landscape that is expected to be more competitive in fiscal 2018, the company’s focus on its 2020 strategy and continued investments in innovating products and brands, will help drive results.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Clorox's (CLX) Long-Term Strategy Bode Well: Here's Why
The Clorox Company (CLX - Free Report) looks good on the back of its long-term initiatives, solid fourth-quarter fiscal 2017 results, strong brand portfolio and a disciplined capital strategy.
Let’s find out more about the stock, which also boasts a long-term earnings growth rate of 6.6%.
2020 Strategy
Clorox remains keen on the smooth execution of its 2020 Strategy, which is aimed at boosting growth for the improvement of categories and overall market share. In fact, the whole strategy is aimed at achieving certain long-term aspirations, including growing net sales by 3−5%, improvement of EBIT margin by 25−50 basis points, and generating free cash flow of 10−12% of sales, all on a yearly basis.
We note that the company is well on track with its 2020 Strategy, which is meant to be achieved through key accelerators like investment in brands; development of eCommerce; technological advancements; enhancement of growth culture and focus on the 3Ds – desire, decision and delight.
Sturdy Q4 Results & Favorable Outlook
Clorox posted solid fourth-quarter fiscal 2017 results, wherein both the top and bottom lines grew year over year and topped estimates. Notably, earnings marked the third straight quarter of a beat, while sales reverted to its positive surprise track after a miss in the last quarter.
While the bottom line gained from strong sales and cost-savings, the top line was fueled by higher volumes, better International pricing and benefits from RenewLife (acquired in May 2016). Further, sales grew year over year in each segment in the quarter. The company’s fiscal 2017 performance also remained robust with solid top- and bottom-line growth year over year. (Read More: Clorox Q4 Earnings & Sales Beat the Zacks Consensus)
Further, management is encouraged by its International operations, and expects pricing and cost savings to continue driving results. It expects fiscal 2018 to represent another year of strong earnings and sales growth. For fiscal 2018, Clorox expects sales to grow in a range of 2–4%, and earnings from continuing operations to rise 3–7% year over year.
Other Strengths
We believe Clorox's diversified brand portfolio places the company well above its peers to generate above-average industry growth and sustain itself in the currently challenging environment.
In fact, its focus on boosting sales through brands is well-evident from its constant innovations and marketing strategies to drive top-line growth. Alongside, it maintains a disciplined capital allocation strategy, making investments to develop its business while using the excess cash to lower debts and enhance shareholder returns.
Concerns/Weakness
However, the stock is not devoid of concerns/headwinds, which might dampen its performance in the near term. Clorox’s significant international presence exposes it to major foreign currency risks (especially in Argentina), which have hurt results for a while in the past. Also, currency headwinds are expected to have one point adverse impact on sales growth in fiscal 2018.
Additionally, Clorox faces intense competition from other well-established players in the consumer products industry, such as Church & Dwight Co., Inc. (CHD - Free Report) , Colgate-Palmolive Company (CL - Free Report) and The Procter & Gamble Company (PG - Free Report) on the basis of pricing, promotional activities and new product introductions.
Bottom Line
While these headwinds, along with a retail landscape that is expected to be more competitive in fiscal 2018, the company’s focus on its 2020 strategy and continued investments in innovating products and brands, will help drive results.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>